- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NCCN Unveils Value Tool for CML and MM
NCCN Evidence Blocks add affordability to Guidelines recommendations on safety, efficacy, quality, and consistency of regimens.
At its 10th Annual Congress on Hematological Malignancies, the National Comprehensive Cancer Network (NCCN) provided details of the NCCN Evidence Blocks for chronic myelogenous leukemia (CML) and multiple myeloma (MM). The announcement of this value calculator had created ripples back in August when it followed the release of ASCO’s Value Framework and the DrugAbacus tool developed by Peter Bach, MD, and his team at the Memorial Sloan Kettering Cancer Center.
"NCCN Evidence Blocks will educate providers and patients about the efficacy, safety, and affordability of systemic therapy, serving as a starting point for shared decision-making based on the individual patient's value system," said Robert W. Carlson, MD, chief executive officer, NCCN.
Read the press release.
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
